Stock data
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS) reported revenue of US$0.00M and net income of US$13.27M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.00M | — | -US$48.95M | US$13.27M | — |
| 2024 | US$1.32M | — | -US$42.91M | -US$34.11M | — |
| 2023 | US$2.24M | — | -US$38.08M | -US$42.19M | — |
| 2022 | US$23.90M | — | -US$28.92M | -US$18.74M | — |
| 2021 | US$60.88M | — | -US$13.39M | -US$17.14M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$22.49M | — |
| 2026-03-31 | — | -US$18.87M | — |
| 2025-12-31 | — | -US$16.86M | — |
| 2025-09-30 | — | US$45.45M | — |
| 2025-06-30 | — | -US$10.11M | — |
| 2025-03-31 | — | -US$5.20M | — |
| 2024-12-31 | — | -US$11.39M | — |
| 2024-09-30 | — | -US$10.35M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.